Gene: B3GNT2

10678
3-Gn-T1|3-Gn-T2|B3GN-T2|B3GNT|B3GNT-2|B3GNT1|BETA3GNT|BGNT2|BGnT-2|beta-1|beta3Gn-T1|beta3Gn-T2
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2
protein-coding
2p15
Ensembl:ENSG00000170340 MIM:605581 Vega:OTTHUMG00000129444 UniprotKB:Q9NY97
NC_000002.12
PubMed|SNP Mapped
1   ANCO-SNPs
ND|AD
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
1.096e-2 (AD)  9.768e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs7605321chr2:62204998 (GRCh38.p7)G>Aalcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OSTM10.828
RPS6KA30.826
SPCS30.816
PTBP30.814
VMP10.813
FAM91A10.812
AGFG10.809
DCK0.805
WDFY10.804
USP150.803

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.474
OR4F29-0.449
S100A1-0.356
EYA2-0.336
NXNL1-0.326
FAM151A-0.314
ADAMTSL5-0.314
PLIN4-0.31
ACOX2-0.302
SALL3-0.3

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C5112952,2',4,4'-tetrabromodiphenyl ether"2,2',4,4'-tetrabromodiphenyl ether affects the expression of B3GNT2 mRNA"24680724
C0140242,4,5,2',4',5'-hexachlorobiphenyl"2,4,5,2',4',5'-hexachlorobiphenyl affects the expression of B3GNT2 mRNA"24680724
C0164032,4-dinitrotoluene"2,4-dinitrotoluene affects the expression of B3GNT2 mRNA"21346803
C4727913-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid3-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid results in decreased expression of B3GNT2 mRNA16788091
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of B3GNT2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of B3GNT2 mRNA"27188386
D000082AcetaminophenAcetaminophen results in increased expression of B3GNT2 mRNA21420995
C015001arsenitearsenite affects the expression of B3GNT2 mRNA22959463
D004958EstradiolEstradiol affects the expression of B3GNT2 mRNA22574217
C006780bisphenol Abisphenol A results in decreased expression of B3GNT2 mRNA29275510
C006780bisphenol Abisphenol A results in increased expression of B3GNT2 mRNA25181051
C006780bisphenol Abisphenol A results in increased methylation of B3GNT2 gene28505145
C000611646bisphenol F[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of B3GNT2 mRNA28628672
D000069286BortezomibBortezomib results in decreased expression of B3GNT2 mRNA20977926
D002737ChloropreneChloroprene results in increased expression of B3GNT2 mRNA23125180
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of B3GNT2 gene20938992
C018021cobaltous chloridecobaltous chloride results in increased expression of B3GNT2 mRNA24386269
D019327Copper SulfateCopper Sulfate results in increased expression of B3GNT2 mRNA19549813
D016572CyclosporineCyclosporine results in decreased expression of B3GNT2 mRNA25562108|2798913
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of B3GNT2 mRNA28628672
D003993Dibutyl PhthalateDibutyl Phthalate results in increased expression of B3GNT2 mRNA21266533
D003993Dibutyl PhthalateDibutyl Phthalate results in decreased expression of B3GNT2 mRNA21266533
D002945CisplatinCisplatin results in increased expression of B3GNT2 mRNA27594783
D002117CalcitriolCalcitriol results in increased expression of B3GNT2 mRNA21592394
D002117Calcitriol[Testosterone co-treated with Calcitriol] results in increased expression of B3GNT2 mRNA21592394
D005485FlutamideFlutamide results in increased expression of B3GNT2 mRNA24136188
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of B3GNT2 gene20938992
D005839GentamicinsGentamicins results in increased expression of B3GNT2 mRNA22061828
C089796hexabromocyclododecanehexabromocyclododecane affects the expression of B3GNT2 mRNA24680724
D017313FenretinideFenretinide results in increased expression of B3GNT2 mRNA28973697
C475919hydroxytamoxifenhydroxytamoxifen results in increased expression of B3GNT2 mRNA16849584
C492448ICG 001ICG 001 results in increased expression of B3GNT2 mRNA26191083
C016517indole-3-carbinolindole-3-carbinol affects the expression of B3GNT2 mRNA21396975
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of B3GNT2 mRNA28628672
D015759Ionomycin[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of B3GNT2 mRNA25613284
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of B3GNT2 mRNA28628672
C561695(+)-JQ1 compound(+)-JQ1 compound results in increased expression of B3GNT2 mRNA25307878
D007632Keratan SulfateB3GNT2 protein results in increased chemical synthesis of Keratan Sulfate12218059
D008558MelphalanMelphalan results in increased expression of B3GNT2 mRNA22363485
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of B3GNT2 gene20938992
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of B3GNT2 mRNA23179753|2718838
D0156551-Methyl-4-phenylpyridinium1-Methyl-4-phenylpyridinium results in increased expression of B3GNT2 mRNA24810058
D008777MethyltestosteroneMethyltestosterone results in increased expression of B3GNT2 mRNA29191790
C568376MT19c compoundMT19c compound results in increased expression of B3GNT2 mRNA21781307
C017096n-butoxyethanoln-butoxyethanol results in decreased expression of B3GNT2 mRNA19812364
C025589ochratoxin Aochratoxin A results in decreased expression of B3GNT2 mRNA22124623
C025589ochratoxin Aochratoxin A results in increased expression of B3GNT2 mRNA22124623
C568608PCI 5002[PCI 5002 co-treated with Zinc] results in increased expression of B3GNT2 mRNA18593933
C006253pirinixic acidpirinixic acid results in decreased expression of B3GNT2 mRNA23811191
D010938Plant OilsPlant Oils results in increased expression of B3GNT2 mRNA23370395
D011441PropylthiouracilPropylthiouracil results in decreased expression of B3GNT2 mRNA24780913
D012715Sesame OilSesame Oil results in decreased expression of B3GNT2 mRNA29191790
C017947sodium arsenitesodium arsenite affects the methylation of B3GNT2 gene28589171
D013739Testosterone[Testosterone co-treated with Calcitriol] results in increased expression of B3GNT2 mRNA21592394
D013739TestosteroneTestosterone results in increased expression of B3GNT2 mRNA21592394
C020806tetrabromobisphenol Atetrabromobisphenol A results in increased expression of B3GNT2 mRNA27914987
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of B3GNT2 mRNA21570461|2468072
D013749Tetrachlorodibenzodioxin[Tetrachlorodibenzodioxin co-treated with TIPARP gene mutant form] results in increased expression of B3GNT2 mRNA25975270
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of B3GNT2 mRNA19770486
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of B3GNT2 mRNA25613284
D014212TretinoinTretinoin results in decreased expression of B3GNT2 mRNA16788091
D014212TretinoinTretinoin results in decreased expression of B3GNT2 mRNA20488242
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of B3GNT2 mRNA"27188386
C012589trichostatin Atrichostatin A results in increased expression of B3GNT2 mRNA26272509
D014520UrethaneUrethane results in increased expression of B3GNT2 mRNA28818685
D014635Valproic AcidValproic Acid affects the expression of B3GNT2 mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of B3GNT2 mRNA23179753
D001335Vehicle EmissionsVehicle Emissions affects the methylation of B3GNT2 gene25560391
D015032Zinc[PCI 5002 co-treated with Zinc] results in increased expression of B3GNT2 mRNA18593933

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0008375acetylglucosaminyltransferase activity-IBA21873635  
GO:0008376acetylgalactosaminyltransferase activity-IBA21873635  
GO:0008499UDP-galactose:beta-N-acetylglucosamine beta-1,3-galactosyltransferase activity-TAS-  
GO:0008532N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase activity-IBA21873635  
GO:0008532N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase activity-IDA9892646  11042166  25279697  
GO:0008532N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase activity-TAS-  
GO:0016758transferase activity, transferring hexosyl groups-IBA21873635  
GO ID GO Term Qualifier Evidence PubMed
GO:0006486protein glycosylation-IBA21873635  
GO:0006493protein O-linked glycosylation-IBA21873635  
GO:0007411axon guidance-IEA-  
GO:0007608sensory perception of smell-IEA-  
GO:0016266O-glycan processing-TAS-  
GO:0018146keratan sulfate biosynthetic process-TAS-  
GO:0030311poly-N-acetyllactosamine biosynthetic process-IBA21873635  
GO:0030311poly-N-acetyllactosamine biosynthetic process-IDA9892646  11042166  25279697  
GO:1990830cellular response to leukemia inhibitory factor-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000139Golgi membrane-TAS-  
GO:0005783endoplasmic reticulum-IBA21873635  
GO:0005794Golgi apparatus-IBA21873635  
GO:0016020membrane-IBA21873635  
GO:0016021integral component of membrane-IEA-  
KEGG ID KEGG Term
hsa00533Glycosaminoglycan biosynthesis - keratan sulfate
hsa00601Glycosphingolipid biosynthesis - lacto and neolacto series
hsa01100Metabolic pathways
Reactome ID Reactome Term Evidence
R-HSA-1430728MetabolismTAS
R-HSA-1630316Glycosaminoglycan metabolismTAS
R-HSA-1638074Keratan sulfate/keratin metabolismTAS
R-HSA-2022854Keratan sulfate biosynthesisTAS
R-HSA-392499Metabolism of proteinsTAS
R-HSA-5173105O-linked glycosylationTAS
R-HSA-597592Post-translational protein modificationTAS
R-HSA-71387Metabolism of carbohydratesTAS
R-HSA-913709O-linked glycosylation of mucinsTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
23577190PADI4 and HLA-DRB1 are genetic risks for radiographic progression in RA patients, independent of ACPA status: results from the IORRA cohort study. (2013)Suzuki TPLoS One